Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about GILEAD SCIENCES
10/20 GILEAD SCIENCES : FDA approves new cancer treatment with Israeli pedigree
10/20 GILEAD SCIENCES : Announces Multiple Scientific Presentations Demonstrating High..
10/19 GILEAD SCIENCES : 2nd gene therapy for blood cancer approved
10/19 GILEAD SCIENCES : Announces Promotion of Alessandro Riva to Executive Vice Presi..
10/19 NASDAQ 100 MOVERS : Ctrp, adbe
10/19 NOVARTIS : FDA OKs 2nd gene therapy for blood cancer; 1st for adults
10/18 GILEAD SCIENCES : Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes..
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18 GILEAD SCIENCES : UMass Medical Center and Dana-Farber Cancer Institute to recei..
10/18 GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
10/18 GILEAD SCIENCES : UMass Medical School shares $7.5M HIV grant
10/17 GILEAD SCIENCES : Announces Promotion of Alessandro Riva to Executive Vice Presi..
10/16 GILEAD SCIENCES : Awards $7.5 Million in Second Round of Grants to Advance HIV C..
10/16 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday Oc..
More most relevant news
All news about GILEAD SCIENCES
10/20 GILEAD SCIENCES : FDA approves new cancer treatment with Israeli pedigree
10/20 GILEAD SCIENCES : Announces Multiple Scientific Presentations Demonstrating High..
10/20 GILEAD SCIENCES : Jumps After FDA Approves Its Kite-Acquired CAR-T Drug
10/19 GILEAD SCIENCES : to Release Third Quarter 2017 Financial Results on Thursday, O..
10/19 GILEAD SCIENCES : Study Findings from Gilead Sciences Provide New Insights into ..
10/19 GILEAD SCIENCES : Patent Issued for Processes and Intermediates for Preparing an..
10/19 GILEAD SCIENCES : Patent Issued for Salts of HIV Inhibitor Compounds (USPTO 9783..
10/19 GILEAD SCIENCES : names new head of oncology therapeutics
10/19 GILEAD SCIENCES : 2nd gene therapy for blood cancer approved
10/19 GILEAD SCIENCES : Announces Promotion of Alessandro Riva to Executive Vice Presi..
More news
Sector news : Bio Therapeutic Drugs
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
10/17DJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
10/20 CytoDyn Dresses HIV Patients In CCR5 Halloween 'Mask'
10/20 Celgene selloff weighs on biotechs, IBB down 1%
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 3 THINGS, OCTOBER 20, 2017 : Gilead's Big Day, Celgene's Bad News In Crohn's, Br..
10/19 BIOTECH FORUM DAILY DIGEST : Spotlighting Ignyta's Big Recent Rally
10/19 What 'Yes' For Its CAR-T Therapy May Mean For Gilead
Latest Tweets
07:42p$GILD a two month consolidation into earnings (Thurs AMC) 
03:05pTime To Trust Gilead Again  
11:01aKBC Group NV Cuts Stake in Gilead Sciences, Inc. $GILD  
08:41aGilead Sciences $GILD Receiving Somewhat Favorable Press Coverage, Report Sho.. 
04:12aGilead Sciences, Inc. $GILD Given a $96.00 Price Target by Berenberg Bank Ana.. 
More tweets
Qtime:1779
Financials ($)
Sales 2017 25 966 M
EBIT 2017 15 929 M
Net income 2017 10 622 M
Debt 2017 13 436 M
Yield 2017 2,60%
P/E ratio 2017 10,13
P/E ratio 2018 11,93
EV / Sales 2017 4,60x
EV / Sales 2018 5,11x
Capitalization 106 B
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 85,3 $
Spread / Average Target 5,0%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES11.73%106 054
REGENERON PHARMACEUTICALS19.69%46 395
VERTEX PHARMACEUTICALS110.07%38 985
ACTELION23.81%29 840
GENMAB14.75%12 865
EXELIXIS, INC.84.17%7 985